September 17, 2014 12:03 PM ET

Biotechnology

Company Overview of Prolong Pharmaceuticals, Inc.

Company Overview

Prolong Pharmaceuticals, Inc., a biotechnology and pharmaceutical manufacturing company, develops biopharmaceutical products for the treatment of anemia. The company focuses on sickle cell anemia, diabetic ischemia, and several trauma indications. Its products include SANGUINATE, an oxygen transfer agent to treat anemia; and protein therapeutics. The company was founded in 2002 and is based in South Plainfield, New Jersey.

300 Corporate Court

Middlesex Business Center

Suite B

South Plainfield, NJ 07080

United States

Founded in 2002

Phone:

908-444-4660

Fax:

908-444-4661

Key Executives for Prolong Pharmaceuticals, Inc.

President
Age: 53
Managing Director of Research and Development
Vice President of Information Services
Director of Development
Compensation as of Fiscal Year 2014.

Prolong Pharmaceuticals, Inc. Key Developments

Prolong Pharmaceuticals, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 04:15 PM

Prolong Pharmaceuticals, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 04:15 PM. Venue: New York Academy of Sciences, New York, United States.

Prolong Pharmaceuticals LLC Appoints Ronald G Jubin as Managing Director, Research and Development

Prolong Pharmaceuticals LLC named Ronald G Jubin, PhD as its managing director, Research and Development. The new managing director, Research and Development will be responsible for pre-clinical discovery, methods development and the advancement of the company's pipeline candidates.

Prolong Announces Encouraging Results from Phase I Hemolytic Disorder Study

Prolong Pharmaceuticals LLC, a biopharmaceutical company, has announced results from its Phase I study of the company's lead product, SANGUINATE. SANGUINATE (PEGylated carboxyhemoglobin bovine) is an intravenous therapeutic that combines the beneficial functions of a carbon monoxide releasing molecule (CORM) with an oxygen transfer agent (OTA) as well as acting as a plasma expander/flow enhancer. Results from animal studies indicate that low dose release of carbon monoxide promotes anti-inflammatory and anti-vasoconstriction effects, while oxygen is actively delivered to regions of low oxygen concentration (ischemia). The Phase I study was a single center, single-blind, placebo-controlled, single dose study of the safety, tolerability and pharmacokinetics of SANGUINATE in healthy subjects. Three dose levels of SANGUINATE (80 mg/kg, 120 mg/kg, and 160 mg/kg) were administered by intravenous infusion to 3 groups. Each group included 8 subjects: 6 subjects who received active treatment (SANGUINATE) and 2 subjects who received placebo comparator (saline). Overall, SANGUINATE was found to be well tolerated. There were no serious adverse events in this study and there were no discontinuations due to adverse events.

Similar Private Companies By Industry

Company Name Region
Phage Biotechnology Corporation United States
DEKALB Genetics Corporation United States
BioControl Systems, Inc. United States
Accelerated Genetics, Inc. United States
LCT BioPharma, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Prolong Pharmaceuticals, Inc., please visit www.prolongpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.